PCOS Is Now PMOS: What the Name Change Means for Women’s Hormone Health

If you’ve been diagnosed with PCOS, you may have noticed something didn’t quite add up. Maybe you never had ovarian cysts, or your symptoms felt like they extended far beyond your reproductive system to include your metabolism, mood, energy, and weight. As it turns out, you weren’t wrong to feel that disconnect.

In May 2026, after more than a decade of research and global collaboration, the medical community officially renamed Polycystic Ovary Syndrome (PCOS) to better reflect what’s actually happening in the body. The condition is now called polyendocrine metabolic ovarian syndrome, or PMOS.

This is a meaningful shift in how we understand, diagnose, and ultimately treat one of the most common hormonal conditions affecting women, and it has real implications for anyone navigating PCOS, perimenopause, menopause, or hormone optimization more broadly.

Why the Name Changed

The revised name was introduced in a paper published in The Lancet and presented at the European Congress of Endocrinology in Prague, marking the end of a process that followed more than a decade of vigorous debate over the need for a name that more precisely and completely describes the condition. Statnews

After hearing from 22,000 people over 11 years, polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome. The level of consensus behind this change is notable. Survey data showed that 86% of patients and 71% of clinicians supported adopting a new, symptom-based and biologically accurate name rather than retaining the original terminology. Statnews AJMC

The reasoning behind the change centers on accuracy. Many women diagnosed with PCOS don’t actually have ovarian cysts. Others experience symptoms that extend far beyond reproductive health, including insulin resistance, weight changes, inflammation, irregular periods, acne, and unwanted hair growth. The old name focused attention on a single possible feature (ovarian cysts), while overlooking the broader hormonal and metabolic picture. Fertility Centers of New England

The “polyendocrine” part of the new name better describes it as an endocrine, or hormone, condition that involves a disturbance in the body’s chemical messenger system with effects that ripple outward, not a condition confined to the ovaries. CNN

What’s Changing, and What Isn’t

Providers will continue looking for the same combination of symptoms that have always been used to identify this condition. The diagnostic process itself isn’t being overhauled. What’s changing is the framework providers and patients use to understand what’s actually driving those symptoms. Illume Fertility

The new terminology captures the endocrine, metabolic, and ovarian dysfunction that drives infertility, menstrual irregularity, and long-term cardiometabolic health risks, conditions that were always part of the picture but weren’t reflected in the name itself.

This reframing matters clinically. It may open doors for treatments that target the underlying metabolic causes, such as managing insulin resistance, to help restore ovulation and improve outcomes that have historically been complicated by the interplay between hormonal and metabolic dysfunction.

The rollout is planned over three years, with updates to medical guidelines used in 195 countries, so you may see both terms used interchangeably for some time as the transition takes place. AJMC

The Bigger Picture: Hormones Don’t Work in Isolation

At Longevità, this name change validates something we’ve built our entire approach around: hormonal health is never just about one system. Whether we’re talking about PMOS, perimenopause, or menopause, the same principle holds true. Your endocrine system functions as an interconnected network, not a collection of isolated symptoms to address one at a time.

This is precisely why the old PCOS framework fell short for so many women. Treating irregular cycles as a standalone reproductive issue, while separately addressing weight changes or skin concerns, missed the underlying connective tissue: insulin resistance, inflammation, and hormone imbalance working together to create the full symptom picture.

The PMOS-Perimenopause Connection

Women with PMOS often enter perimenopause with a hormonal landscape that’s already been shaped by years of insulin resistance and androgen excess. This doesn’t mean perimenopause will be more difficult, but it does mean a comprehensive understanding of your hormonal history, including a PMOS diagnosis, if applicable, matters when developing a perimenopausal care plan.

Metabolic patterns established earlier in life don’t simply disappear at menopause. If insulin resistance was part of your PMOS picture, it’s worth monitoring closely as estrogen and progesterone shift during perimenopause, since these hormonal changes can compound existing metabolic challenges.

Why Comprehensive Evaluation Matters More Than Ever

The PMOS name change reinforces an approach we’ve long prioritized: looking at the full hormonal and metabolic picture rather than treating individual symptoms in isolation. This is the same philosophy that underlies effective bioidentical hormone replacement therapy (BHRT).

When we evaluate a patient for hormone optimization, we’re not simply checking estrogen and progesterone levels in a vacuum. We’re looking at how those hormones interact with insulin sensitivity, thyroid function, cortisol, and metabolic markers. The PMOS framework essentially applies this same systems-based thinking to a condition that’s long needed it.

What This Means If You’ve Been Diagnosed with PCOS

If you’ve carried a PCOS diagnosis, particularly if your symptoms never fully matched what the name suggested, this shift may bring some validation. It confirms that your experience of widespread, interconnected symptoms wasn’t a misunderstanding of your own diagnosis. It was a limitation of the terminology itself.

It’s also worth using this moment to revisit your care plan. If your treatment has focused narrowly on managing irregular cycles or fertility without addressing the broader metabolic and hormonal factors, a more comprehensive evaluation may reveal opportunities you haven’t yet explored.

What This Means as You Approach Perimenopause and Menopause

Whether or not you’ve been diagnosed with PCOS or PMOS, this name change offers a useful lesson for navigating any hormonal transition: symptoms rarely exist in isolation, and effective care requires looking at the whole system.

This is the foundation of our approach to BHRT. Hot flashes, weight changes, mood shifts, fatigue, and cognitive fog during perimenopause and menopause are connected, driven by the same underlying hormonal shifts, often compounded by metabolic factors like insulin resistance and inflammation. Addressing them one by one, without understanding how they relate to each other, rarely produces lasting results.

The Takeaway

The PCOS-to-PMOS name change is more than updated terminology. It’s an acknowledgment that hormonal conditions in women have long been oversimplified, and that better language leads to better understanding, diagnosis, and treatment.

At Longevità, this validates the comprehensive, whole-system approach we’ve always taken to women’s hormone health. Whether you’re navigating PMOS, perimenopause, menopause, or simply trying to understand why you don’t feel like yourself, the path forward is the same: comprehensive evaluation that looks at how your hormones, metabolism, and overall health connect, not isolated treatment of individual symptoms.

Ready for a Comprehensive Approach to Your Hormone Health?

If you’re navigating PMOS, approaching perimenopause, or experiencing symptoms that haven’t been fully explained by individual treatments, we’d love to connect with you for a personal consultation. Our approach looks at your complete hormonal and metabolic picture to develop a plan that addresses the full scope of what you’re experiencing, and adjusts as your needs change. Call 585.244.1506 or contact us online.

References

1. Teede, H. et al. (2026). International Consensus on Renaming Polycystic Ovary Syndrome. The Lancet. Published May 12, 2026.
2. American Society for Reproductive Medicine. (2026). PCOS Is Now PMOS: Understanding the Name Change. Retrieved from https://www.asrm.org/news-and-events/asrm-news/latest-news/may-27-2026-pcos-is-now-pmos-understanding-the-name-change/
3. Healthline. (2026, May 13). PCOS Is Renamed PMOS. Doctors Say It Will Improve Diagnosis, Treatment. Retrieved from https://www.healthline.com/health-news/pcos-renamed-pmos-improve-diagnosis-care-multisystem-disease
4. STAT News. (2026, May 12). PCOS’s new name is PMOS, a small letter change that required a big scientific process. Retrieved from https://www.statnews.com/2026/05/12/pcos-now-called-pmos-polyendocrine-metabolic-ovarian-syndrome/
5. University of Rochester Medicine. (2026). PCOS Is Now PMOS: Why This Name Change Matters. Retrieved from https://www.urmc.rochester.edu/news/publications/health-matters/pcos-is-now-pmos-why-this-name-change-matters
6. CNN. (2026, May 13). PCOS gets a new name: PMOS. Retrieved from https://www.cnn.com/2026/05/13/health/pcos-name-change-pmos-wellness
7. AJMC. (2026). PCOS Renamed PMOS in Landmark Shift Reflecting Metabolic and Endocrine Features. Retrieved from https://www.ajmc.com/view/pcos-renamed-pmos-in-landmark-shift-reflecting-metabolic-and-endocrine-features